Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Murthy

Showing results (871-880 of 873) with videos related to

Pageof 88
Sort By:
You have reached the last page of results.This site can display upto 873 results.
The New England Journal of Medicine|October 17, 2019
Randomized Trial of Medical versus Surgical Treatment for Refractory HeartburnStuart J Spechler, John G Hunter, Karen M Jones, et al.
Journal of the Canadian Association of Gastroenterology|September 7, 2023
The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel DiseaseLaura E Targownik, Natasha Bollegala, Vivian H Huang, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
Pageof 88

Showing results (871-880 of 873) with videos related to

Sort By:
Pageof 88
You have reached the last page of results.This site can display upto 873 results.
The New England Journal of Medicine|October 17, 2019
Randomized Trial of Medical versus Surgical Treatment for Refractory HeartburnStuart J Spechler, John G Hunter, Karen M Jones, et al.
Journal of the Canadian Association of Gastroenterology|September 7, 2023
The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel DiseaseLaura E Targownik, Natasha Bollegala, Vivian H Huang, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
Pageof 88